3 Biggest Pharma Giants: Buy, Sell or Hold?
All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.
The three biggest US pharma names by market cap trade at very different setups right now: Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) at $247.02 screens as the most compelling on fundamentals, Eli Lilly (NYSE:LLY) at $1,156.63 looks fully valued, and AbbVie (NYSE:ABBV) at $244.11 appears stretched relative to its growth outlook. Each has run hard off 2025 lows, and the fundamentals no longer line up the same way.
Johnson & Johnson: The Rerating Has Legs
J&J has posted four straight EPS beats and accelerating revenue growth, from +5.8% in Q2 2025 to +9.9% in Q1 2026. Management raised 2026 guidance to $100.3B–$101.3B in sales and $11.45–$11.65 in adjusted EPS. DARZALEX at $3.96B (+22.5%) and TREMFYA at $1.61B (+68.3%) are more than absorbing the STELARA biosimilar cliff.
The setup: shares are up 20.69% year to date and 63.17% over one year, yet the stock trades at a forward P/E of 22, backed by a 2.02% dividend yield and 64 consecutive years of hikes.
Analysts carry a $262.27 consensus target against the current $247.02, with 15 Buy, 7 Hold, 1 Sell. Targets are not guarantees, but the Orthopaedics separation and Enterprise Business Review on December 8, 2026 are near-term catalysts. Litigation charges of $330M in Q1 remain the swing factor to watch.
Eli Lilly: Great Company, Priced for Perfection
Lilly’s Q1 2026 revenue jumped 55.5% to $19.80B with adjusted EPS of $8.55 beating $6.79 estimates by 25.88%. Mounjaro hit $8.66B (+125%) and Zepbound reached $4.16B (+80%). Guidance was lifted to $82B–$85B revenue and $35.5–$37 EPS, and the Foundayo oral GLP-1 approval opens a larger addressable pool.
The challenge is price. Shares have already climbed 50.92% over one year and 421.48% over five, and the stock trades at a trailing P/E of 42 and forward P/E of 33.
Realized prices fell 13% in Q1, Mounjaro and Zepbound together account for 64.7% of revenue, and prediction-market sentiment has slipped 21.4 points over 30 days. With 23 Buy, 5 Hold, 2 Sell and a $1,254.07 target implying modest upside, the risk/reward argues for patience until pricing and competition stabilize.
AbbVie: The Multiple Has Detached From the Math
Skyrizi at $4.48B (+30.9%) and Rinvoq at $2.12B (+23.3%) are outrunning Humira erosion (Humira at $688M, down 38.6%), and 2026 EPS guidance was nudged to $14.08–$14.28. That is a real business. The valuation is the sticking point.
ABBV trades at a trailing P/E of 122 and price-to-book of 50, on negative book value of -$3.77, after rising 35.04% over one year and 481.43% over ten.
Q1 adjusted EPS of $2.65 missed by 0.66%, weighed by $744M in IPR&D charges on top of $5B for full-year 2025. Analysts still model a $265.50 target with 24 Buy, 6 Hold, 1 Sell, but one predictive model implies -30.9% downside to $168.67. With growth concerns building beyond 2028 and Imbruvica down 24.7%, the risk/reward has narrowed.
The bottom line
All three stocks have outrun the S&P 500’s mid-single-digit gain year to date. J&J’s rerating still has room on the fundamentals, Lilly’s setup argues for patience after a strong run, and AbbVie’s multiple looks demanding relative to the growth math. This is analysis, not investment advice — investors should weigh their own objectives and risk tolerance.
Contact [email protected] for any questions or corrections.
Vandita Jadeja is a financial copywriter who loves to read and write about stocks. She believes in buying and holding for long term gains. Her knowledge of words and numbers helps her write clear stock analysis. She has contributed to several publications, including the Joy Wallet, Benzinga, The Motley Fool and InvestorPlace.
